MDS and AML Moon Shot Update
Overcoming Resistance to Hypomethylating Drugs
Treatment with hypomethylating agents (HMAs) is the current standard of care for MDS and elderly patients with AML. While these drugs are effective, patients inevitably develop resistance. Our Moon Shot team aims to uncover the molecular features and pathways of MDS and AML cells that lead to resistance to hypomethylating agents (HMAs). The key biological pathways that are identified will then be targeted therapeutically through rational clinical trial strategies. We’re also addressing ways to detect and prevent therapy-related MDS, which exhibits extreme resistance to HMAs.